November 9, 2020 - Regulatory SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
November 6, 2020 - Regulatory Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB
October 20, 2020 - Regulatory Shareholders of SynAct Pharma proposes Uli Hacksell as new board member
October 12, 2020 - Regulatory English version of PR published 20201012 at 07.33AM SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis
September 23, 2020 - Regulatory Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter
September 23, 2020 - Regulatory SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients
September 3, 2020 - Regulatory SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed
September 1, 2020 - Regulatory SynAct Pharma Informs about Termination of Coverage Agreement with Redeye
August 28, 2020 - Regulatory SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections
July 27, 2020 - Regulatory Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4
July 15, 2020 - Regulatory SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis
June 30, 2020 - Regulatory SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020
June 29, 2020 - Regulatory SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
June 25, 2020 - Regulatory SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2
June 2, 2020 - Regulatory SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
May 25, 2020 - Regulatory SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases
May 5, 2020 - Regulatory SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression
March 31, 2020 - Regulatory SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
March 31, 2020 - Regulatory Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
